CA3160666A1 - Inhibitor of apoptosis (iap) protein antagonists - Google Patents
Inhibitor of apoptosis (iap) protein antagonistsInfo
- Publication number
- CA3160666A1 CA3160666A1 CA3160666A CA3160666A CA3160666A1 CA 3160666 A1 CA3160666 A1 CA 3160666A1 CA 3160666 A CA3160666 A CA 3160666A CA 3160666 A CA3160666 A CA 3160666A CA 3160666 A1 CA3160666 A1 CA 3160666A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cancer
- stereoisomer
- pharmaceutically acceptable
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933190P | 2019-11-08 | 2019-11-08 | |
| US62/933,190 | 2019-11-08 | ||
| PCT/US2020/059552 WO2021092500A1 (en) | 2019-11-08 | 2020-11-06 | Inhibitor of apoptosis (iap) protein antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3160666A1 true CA3160666A1 (en) | 2021-05-14 |
Family
ID=75849612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3160666A Pending CA3160666A1 (en) | 2019-11-08 | 2020-11-06 | Inhibitor of apoptosis (iap) protein antagonists |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230115837A1 (https=) |
| EP (1) | EP4058454A4 (https=) |
| JP (2) | JP7659553B2 (https=) |
| AU (1) | AU2020380818A1 (https=) |
| CA (1) | CA3160666A1 (https=) |
| WO (1) | WO2021092500A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020110056A1 (en) * | 2018-11-30 | 2020-06-04 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in hiv therapy |
| CA3160666A1 (en) * | 2019-11-08 | 2021-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| AU2021265826B2 (en) * | 2020-04-30 | 2026-03-19 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (IAP) protein antagonists |
| CN117304253A (zh) * | 2022-06-22 | 2023-12-29 | 中国药科大学 | 一种二氮杂双环拟肽衍生物的制备方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| NZ572531A (en) * | 2006-05-05 | 2011-09-30 | Univ Michigan | Bivalent smac mimetics and the uses thereof |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| US8551955B2 (en) * | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
| US9546174B2 (en) * | 2012-11-30 | 2017-01-17 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (IAP) antagonists |
| JP6768522B2 (ja) * | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| KR20180107261A (ko) * | 2016-02-16 | 2018-10-01 | 메사추세츠 인스티튜트 오브 테크놀로지 | Myc 조정제로서의 MAX 결합제 및 그의 용도 |
| US10870663B2 (en) * | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| WO2020110056A1 (en) * | 2018-11-30 | 2020-06-04 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in hiv therapy |
| CA3160666A1 (en) * | 2019-11-08 | 2021-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
-
2020
- 2020-11-06 CA CA3160666A patent/CA3160666A1/en active Pending
- 2020-11-06 JP JP2022525958A patent/JP7659553B2/ja active Active
- 2020-11-06 US US17/773,749 patent/US20230115837A1/en active Pending
- 2020-11-06 EP EP20886024.7A patent/EP4058454A4/en active Pending
- 2020-11-06 WO PCT/US2020/059552 patent/WO2021092500A1/en not_active Ceased
- 2020-11-06 AU AU2020380818A patent/AU2020380818A1/en active Pending
-
2025
- 2025-03-27 JP JP2025054317A patent/JP2025118594A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023513655A (ja) | 2023-04-03 |
| AU2020380818A1 (en) | 2022-06-02 |
| JP2025118594A (ja) | 2025-08-13 |
| EP4058454A4 (en) | 2023-12-13 |
| WO2021092500A1 (en) | 2021-05-14 |
| JP7659553B2 (ja) | 2025-04-09 |
| US20230115837A1 (en) | 2023-04-13 |
| EP4058454A1 (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912786B2 (en) | Inhibitor of apoptosis protein (IAP) antagonists | |
| EP3894392A1 (en) | Compositions and methods for the treatment of cancer | |
| JP7659553B2 (ja) | アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト | |
| EP2922538B1 (en) | Azaindole derivatives as jak3 inhibitors | |
| US9932329B2 (en) | Benzimidazole derivatives as RLK and ITK inhibitors | |
| WO2017190109A1 (en) | Sigma receptor binders | |
| AU2019201104A1 (en) | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression and neuropathic pain | |
| AU2021265826B2 (en) | Inhibitor of apoptosis (IAP) protein antagonists | |
| WO2023081290A1 (en) | Inhibitor of apoptosis (iap) protein antagonists | |
| WO2020028525A1 (en) | Sumo inhibitor compounds and uses thereof | |
| WO2025240412A1 (en) | Methods for the treatment of cancer | |
| WO2025240416A1 (en) | Compositions and methods for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20241129 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250204 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250409 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250409 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260210 |